{"id":69538,"date":"2024-08-25T15:46:18","date_gmt":"2024-08-25T15:46:18","guid":{"rendered":"https:\/\/www.pharmacie-vezere.com\/promotions\/?p=69538"},"modified":"2024-09-02T11:21:51","modified_gmt":"2024-09-02T11:21:51","slug":"organon-et-lilly-etendent","status":"publish","type":"post","link":"https:\/\/www.pharmacie-vezere.com\/promotions\/organon-et-lilly-etendent\/","title":{"rendered":"Organon et Lilly \u00e9tendent leur accord pour le traitement de la migraine \u00e0 de nouveaux march\u00e9s"},"content":{"rendered":"

Organon et Eli Lilly and Company ont \u00e9largi leur accord commercial, selon lequel Organon deviendra le distributeur et promoteur exclusif du m\u00e9dicament contre la migraine<\/a> Emgality (galcanezumab) sur 11 nouveaux march\u00e9s.
\nL’expansion comprend le Canada, la Colombie, Isra\u00ebl, le Kowe\u00eft, le Mexique, le Qatar, l’Arabie Saoudite, la Cor\u00e9e du Sud, Ta\u00efwan, la Turquie et les \u00c9mirats Arabes Unis.<\/p>\n

Les termes financiers de l’accord incluent un paiement initial de 22,5 millions de dollars \u00e0 Lilly, ainsi que des paiements d’\u00e9tape suppl\u00e9mentaires bas\u00e9s sur les ventes.
\nCet accord s’appuie sur les responsabilit\u00e9s de distribution existantes d’Organon pour le produit en Europe depuis f\u00e9vrier 2024.<\/p>\n

Kevin Ali<\/a>, PDG d’Organon, a d\u00e9clar\u00e9 : “L’\u00e9largissement de cet accord t\u00e9moigne des capacit\u00e9s de commercialisation de premier ordre d’Organon, de sa pr\u00e9sence mondiale et de son expertise approfondie en mati\u00e8re de sant\u00e9 des femmes. Nous savons que la migraine est la principale cause d’invalidit\u00e9 chez les jeunes femmes et nous sommes fiers d’\u00e9largir notre offre \u00e0 plus de femmes et d’hommes dans le monde vivant avec des migraines \u00e9pisodiques ou chroniques.”<\/p>\n

Emgality, un anticorps monoclonal humanis\u00e9, agit comme un antagoniste du peptide li\u00e9 au g\u00e8ne de la calcitonine. Il est con\u00e7u comme un traitement pr\u00e9ventif de la migraine chez les adultes et, sur certains march\u00e9s, est sp\u00e9cifiquement indiqu\u00e9 pour les patients qui connaissent au moins quatre jours de migraine par mois. Dans certaines r\u00e9gions, le m\u00e9dicament est \u00e9galement approuv\u00e9 pour le traitement des c\u00e9phal\u00e9es en grappe \u00e9pisodiques chez les adultes.<\/p>\n

Selon l’accord \u00e9largi, Organon assumera l’enti\u00e8re responsabilit\u00e9 de la distribution et de la promotion d’Emgality sur les march\u00e9s nouvellement ajout\u00e9s. Lilly conservera son r\u00f4le de titulaire de l’autorisation de mise sur le march\u00e9 et continuera \u00e0 fabriquer le produit pour la vente.<\/p>\n

Ilya Yuffa, vice-pr\u00e9sident ex\u00e9cutif d’Eli Lilly and Company et pr\u00e9sident de Lilly International, a d\u00e9clar\u00e9 : “Nous sommes ravis d’\u00e9tendre cet accord de collaboration avec Organon. Nous sommes confiants dans notre mission commune d’apporter ce traitement important contre la migraine \u00e0 plus de patients dans le monde.”<\/p>\n

Ce d\u00e9veloppement fait suite \u00e0 l’acquisition r\u00e9cente de Morphic Holding par Eli Lilly pour 3,2 milliards de dollars, visant \u00e0 renforcer son portefeuille de maladies inflammatoires de l’intestin.<\/p>\n","protected":false},"excerpt":{"rendered":"

Organon et Eli Lilly and Company ont \u00e9largi leur accord commercial, selon lequel Organon deviendra le distributeur et promoteur exclusif du m\u00e9dicament contre la migraine Emgality (galcanezumab) sur 11 nouveaux march\u00e9s. L’expansion comprend le Canada, la Colombie, Isra\u00ebl, le Kowe\u00eft, le Mexique, le Qatar, l’Arabie Saoudite, la Cor\u00e9e du Sud, Ta\u00efwan, la Turquie et les […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[684],"tags":[],"class_list":["post-69538","post","type-post","status-publish","format-standard","hentry","category-nouvelles-pharmaceutiques"],"_links":{"self":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/comments?post=69538"}],"version-history":[{"count":2,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69538\/revisions"}],"predecessor-version":[{"id":69540,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69538\/revisions\/69540"}],"wp:attachment":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media?parent=69538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/categories?post=69538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/tags?post=69538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}